(-0.17%) 5 058.25 points
(-0.02%) 37 984 points
(-0.45%) 17 492 points
(-0.98%) $81.13
(-2.81%) $1.935
(-0.15%) $2 299.40
(0.38%) $26.76
(-0.34%) $945.00
(0.13%) $0.938
(0.31%) $11.13
(0.12%) $0.801
(0.11%) $93.56
0.00% ¥ 1 542.00
Live Chart Being Loaded With Signals
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally...
Stats | |
---|---|
Dagens volum | 139 800 |
Gjennomsnittsvolum | 345 032 |
Markedsverdi | 64.20B |
EPS | ¥0 ( 2024-02-01 ) |
Neste inntjeningsdato | ( ¥12.99 ) 2024-05-08 |
Last Dividend | ¥30.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 11.67 |
ATR14 | ¥0.762 (0.05%) |
Volum Korrelasjon
Shin Nippon Biomedical Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Shin Nippon Biomedical Korrelasjon - Valuta/Råvare
Shin Nippon Biomedical Økonomi
Annual | 2022 |
Omsetning: | ¥25.09B |
Bruttogevinst: | ¥13.05B (52.00 %) |
EPS: | ¥145.57 |
FY | 2022 |
Omsetning: | ¥25.09B |
Bruttogevinst: | ¥13.05B (52.00 %) |
EPS: | ¥145.57 |
FY | 2022 |
Omsetning: | ¥17.75B |
Bruttogevinst: | ¥9.69B (54.58 %) |
EPS: | ¥171.20 |
FY | 2021 |
Omsetning: | ¥15.11B |
Bruttogevinst: | ¥7.55B (49.99 %) |
EPS: | ¥87.95 |
Financial Reports:
No articles found.
Shin Nippon Biomedical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥20.00 (N/A) |
¥0 (N/A) |
¥30.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥0.500 | 2004-03-26 |
Last Dividend | ¥30.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 15 | -- |
Total Paid Out | ¥99.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.65 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.81 | |
Div. Directional Score | 7.68 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8159.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7525.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6748.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
6089.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
4771.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4016.T | Ex Dividend Junior | 2023-11-29 | Annually | 0 | 0.00% | |
3222.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
2217.T | Ex Dividend Junior | 2024-01-30 | Annually | 0 | 0.00% | |
9075.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7966.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.206 | 1.500 | 5.88 | 8.82 | [0 - 0.5] |
returnOnAssetsTTM | 0.0771 | 1.200 | 7.43 | 8.92 | [0 - 0.3] |
returnOnEquityTTM | 0.192 | 1.500 | 8.98 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.496 | 0.800 | 7.52 | 6.02 | [1 - 3] |
quickRatioTTM | 0.835 | 0.800 | 9.80 | 7.84 | [0.8 - 2.5] |
cashRatioTTM | 0.571 | 1.500 | 7.94 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.374 | -1.500 | 3.77 | -5.65 | [0 - 0.6] |
interestCoverageTTM | 30.41 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 85.79 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 85.79 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.884 | -1.500 | 6.46 | -9.69 | [0 - 2.5] |
grossProfitMarginTTM | 0.522 | 1.000 | 4.63 | 4.63 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.150 | 1.000 | 9.01 | 9.01 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.134 | 1.000 | -0.368 | -0.368 | [0.2 - 2] |
assetTurnoverTTM | 0.374 | 0.800 | -0.839 | -0.671 | [0.5 - 2] |
Total Score | 10.55 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.67 | 1.000 | 8.92 | 0 | [1 - 100] |
returnOnEquityTTM | 0.192 | 2.50 | 9.34 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 85.79 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.24 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 85.79 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.779 | 1.500 | -8.53 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.134 | 1.000 | 9.16 | 0 | [0.1 - 0.5] |
Total Score | 4.81 |
Shin Nippon Biomedical
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.